Quantitative proteomics reveals regulatory differences in the chondrocyte secretome from human medial and lateral femoral condyles in osteoarthritic patients by unknown
Stenberg et al. Proteome Science 2013, 11:43
http://www.proteomesci.com/content/11/1/43RESEARCH Open AccessQuantitative proteomics reveals regulatory
differences in the chondrocyte secretome from
human medial and lateral femoral condyles in
osteoarthritic patients
Johan Stenberg1†, Ulla Rüetschi1†, Eva Skiöldebrand2, Johan Kärrholm3 and Anders Lindahl1,4*Abstract
Background: Osteoarthritis (OA) is a destructive joint disease and there are no known biomarkers available for an
early diagnosis. To identify potential disease biomarkers and gain further insight into the disease mechanisms of OA
we applied quantitative proteomics with SILAC technology on the secretomes from chondrocytes of OA knees,
designated as high Mankin (HM) scored secretome. A quantitative comparison was made between the secretomes
of the medial and lateral femur condyle chondrocytes in the same knee since the medial femur condyle is usually
more affected in OA than the lateral condyle, which was confirmed by Mankin scoring. The medial/lateral
comparison was also made on the secretomes from chondrocytes taken from one individual with no clinically
apparent joint-disease, designated as low Mankin (LM) scored secretome.
Results: We identified 825 proteins in the HM secretome and 69 of these showed differential expression when
comparing the medial and lateral femoral compartment. The LM scored femoral condyle showed early signs of OA
in the medial compartment as assessed by Mankin score. We here report the identification and relative
quantification of several proteins of interest for the OA disease mechanism e.g. CYTL1, DMD and STAB1 together
with putative early disease markers e.g. TIMP1, PPP2CA and B2M.
Conclusions: The present study reveals differences in protein abundance between medial/lateral femur condyles in
OA patients. These regulatory differences expand the knowledge regarding OA disease markers and mechanisms.
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Osteoarthritis (OA) is a complex age-related polygenetic
progressive degenerative disease of the synovial joint char-
acterized by gradual destruction of the articular cartilage
and subchondral bone leading to a loss of joint function.
The gradual destruction of the articular cartilage causes
joint pain and stiffness, which slowly disables the patient.
The OA disease could affect a single joint, several joints or* Correspondence: anders.lindahl@clinchem.gu.se
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reproduction in any medium, provided the orbe more generalized. The disease prevalence is higher in
women [1-4] and when the knee joint is affected in OA
there is a predominant tissue degradation of the medial
compartment as compared to the lateral compartment
[1,2,5]. Due to the lack of disease modifying treatments
the only treatment option for the degenerated joint is
eventually a total joint replacement. However, isolated
moderate to large knee cartilage defects due to trauma
benefit from autologous chondrocytes transplantation pro-
cedures [6,7].
The etiology of OA is still elusive although many studies
have been performed in order to find pathological media-
tors and biomarkers [8-11]. When searching for disease
processes in OA the whole joint should be considered a
diseased organ where the synovium, articular chondrocytesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Mankin score of the six monolayer cultured
specimens




HM 1 67 10.3 4
HM 2 72 11 5.7
HM 3 72 8.3 4.7
HM 4 69 9 4
HM 5 63 10.3 6.3
LM 70 2.7 0.3
High Mankin Score (HM) Low Mankin Score (LM).
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tors, which may have catabolic and/or anabolic effects on
articular cartilage [12-15]. Inflammation has been proposed
to cause catabolic processes in the joint resulting in cartil-
age erosion, see Abramson and Attur [16] for a compre-
hensive review. Signaling pathways as well as autocrine
and paracrine mediators have been studied in OA in order
to reveal the processes behind the slow regeneration of car-
tilage [17] and to identify putative drug targets [18]. There
have been several genome-wide association studies of
osteoarthritis and one of the largest is the arcOGEN study
that in its first report from a genome-wide association scan
for knee and hip osteoarthritis in 3,177 cases and 4,894
population-based controls was unable to find a genetic
linkage to the disease. The conclusion from the study was
that “data suggests that osteoarthritis is a highly polygenic
disease with multiple risk variants conferring small effects”
and that additional larger populations studies are needed
[19]. In a second report five genome-wide significant foci
were identified [20]. When searching the OMIM database
for genes connected to OA GDF5 and FRZB among others
are considered potential candidates.
The introduction of global proteomic techniques enables
studies of the functional proteome after posttranslational
modifications and protein processing, which give a more
comprehensive picture in the evaluation of disease hypoth-
esis than solely gene expression analysis. Stable isotope la-
beling by amino acids in cell culture (SILAC) is a metabolic
labeling technique that incorporates nonradioactive isotope
labeled amino acids in all newly synthesized proteins [21].
The isotope labeled proteome from one cell culture can be
qualitatively and quantitatively compared to another culture
condition or cell line cultured with normal amino acids
using mass spectrometry (MS). Hence, SILAC combined
with MS makes a powerful tool capable of analyzing
global proteomic variances. Cultured chondrocytes
from OA patients have been studied [22-24] in func-
tional and comparative studies and SILAC approaches
in cartilage explants have been tried out but failed to
label the total proteome [22].
Our primary hypothesis was that the secretome from
culture expanded OA chondrocytes is relevant when com-
pared to the cartilage explants secretome. Secondly we hy-
pothesized that since in OA the medial compartment of
the knee joint is more often and more severely affected as
compared to the lateral compartment, differences should
exist in the secretomes since the cells originate from car-
tilage with different grades of degeneration. Further, the
potential protein abundance differences could expand the
knowledge regarding OA disease markers and mecha-
nisms. We here demonstrate that the SILAC technology
enables a unique bilateral comparison in the same patient
with new interesting results and to our knowledge this is
the first time such a comparison has been done.Results
Characterization of cartilage biopsies for monolayer cultures
Total knee replacement biopsies from five OA patients, in-
cluded in the monolayer culture, were characterized by
Mankin score and designated high Mankin scored (HM)
patients. The characterization resulted in an average
Mankin score for the femoral medial condyle of 9.8 and
for the femoral lateral condyle of 4.9 (Table 1). The same
characterization was done for the macroscopically healthy
cartilage from one individual, which received Mankin
score 2.7 for the medial femoral condyle and 0.3 for the
lateral femoral condyle (Table 1) and was subsequently
designated as a low Mankin score (LM) patient although
the medial condyle was slightly affected by an early OA.
The relevance of monolayer culture as an experimental
model to study the chondrocyte secretome
A previous report has demonstrated the difficulty to in-
corporate stable isotope labels into proteins in cartilage
explant cultures with a relatively small number of identi-
fied labeled proteins as a result [22]. This is in agreement
with our own results from SILAC labeling of OA explants
where stable isotope labeled proteins were present at very
low abundance and thus not useful for quantitative ana-
lysis (data not shown). We therefore performed stable iso-
tope labeling with amino acids in cell culture (SILAC) of
chondrocytes in monolayer cultures. However, in order to
evaluate the monolayer culture as an experimental model
relevant for studies of differences in the secretome of
medial femur condyle and lateral femur condyle positions
of the OA knee joint we compared the secretomes in the
OA explants and monolayer cultures. For this specific
comparison we used the combined secretomes identified
from the five monolayer cultures isolated from OA cartil-
age with high Mankin score and the combined secretomes
from the two OA cartilage explants. In the supernatants of
OA cartilage explant cultures we identified a total of
344 protein groups at a false discovery rate (FDR) of 1%
(Additional file 1: Table S1). An additional filtering for
proteins identified with at least two peptides was made,
which yielded 320 protein groups. Monolayer cultures of
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individuals were grown to full labeling and conditioned
with serum-free media for 24 hours. Analysis of the super-
natants from the HM monolayer cultures identified a total
of 825 protein groups at a FDR of 1% (Additional file 2:
Table S2) and additional filtering for proteins identified
with at least two peptides yielded 727 protein groups. A
comparison of the identified proteins from cartilage ex-
plants and monolayer cultured chondrocytes filtered for
1% FDR and identified with at least two peptides
showed that 172 proteins were identified in both
groups, which represented 54% of the proteins identi-
fied in the explant secretome (Additional file 3: Table
S3). Polacek et al. used chondrocytes from autologous
chondrocyte implantations (ACI) to establish mono-
layer cultures. Out of the 100 unique proteins identified
from their analysis 84 overlapped with our study.
Among the proteins identified in both explant and
monolayer cultures were several cartilage extracellular
matrix remodeling (ECM) proteins, e.g. cartilage oligo-
meric matrix protein (COMP), matrix metalloproteinase
(MMP)-1, -2, -3 and −10, metalloproteinase inhibitor
(TIMP) 1 and 2 and several isoforms of collagen. Gen-
etic association for disease analysis of the 172 proteins
common for both monolayer chondrocytes and explant
cultures showed the term osteoarthritis to be highly
connected to the protein list (P-value ≤ 0.01). Gene
ontology analysis for biological process of the 172 com-
mon proteins also showed the most enriched terms to be
involved in ECM organization and inflammation processes
further supporting the hypothesis that the monolayer cul-
tured OA chondrocytes could partly represent the OA
secretome (Additional file 4: Table S4, sheet 1). However
the well-known loss of phenotype of chondrocytes when
subjected to monolayer cultures was also demonstrated by
presence of Collagen type I alpha 1 and 2 subunits and ab-
sence of Collagen type II subunits in the monolayer
secretome (Additional file 2: Table S2).
Secretome profile of high and low Mankin scored femur
chondrocytes
The proteomic analysis of the chondrocyte secretomes
from five OA patients undertaking a total knee replacement
operation resulted in a comprehensive secretome profile of
femoral condyle knee OA chondrocytes. In total, 825 pro-
tein groups were identified with a 1% FDR (Additional file
2: Table S2). The corresponding analysis of a low Mankin
scored individual resulted in 528 identified protein groups
(Additional file 5: Table S5). Gene ontology enrichment
analysis of the high Mankin scored secretome regarding
cellular compartment and biological process using the
DAVID bioinformatics resource showed the highest
statistical significance for the GO terms GO:0044421
extracellular region part and GO:0030198 extracellularmatrix organization (Additional file 4: Table S4, sheet 2–3).
The corresponding analysis of the low Mankin scored
secretome showed high statistical significance for the GO
term GO:0044421 extracellular region part and interestingly
high statistical significance for the biological process terms
GO:0030199 collagen fibril organization and GO:0006916
anti-apoptosis (Additional file 4: Table S4, sheet 4–5).
Differentially expressed proteins in the femur medial and
lateral knee compartments in OA patients
The secretome analysis from femoral condyle medial and
lateral high Mankin chondrocytes within the same knee of
five OA patients showed significant differences in the pro-
tein amounts of 69 proteins, (Table 2 and Additional file
6: Table S6), among these, 28 protein groups were medi-
ally abundant and 41 were laterally abundant (Figure 1).
Six proteins were significantly regulated in at least three
out of five patients, when comparing the medial and lat-
eral positions. Gene ontology biological process term en-
richment analysis of the significantly regulated high
Mankin scored secretome showed the highest statistically
significant enrichment of the terms GO:0006954 inflam-
matory response and GO:0009611 response to wounding
(Additional file 4: Table S4, sheet 6). Proteins involved in
these processes were Transferrin, Stabilin1, Insulin, Clusterin,
S100 calcium binding protein A9, Annexin A1, Desmoplakin,
Enolase 3, Complement component 1, r subcomponent,
Insulin-like growth factor binding protein 4 and Macrophage
migration inhibitory factor. Cellular compartment gene
ontology analysis also showed the highest significance for
GO:0005576 extracellular region (Additional file 4: Table S4,
sheet 7).
Differentially expressed proteins in the femur medial and
lateral knee compartments in a low Mankin scored patient
Histograms of Log2 values of the protein Heavy/Light (H/
L) ratios for the low Mankin scored individual were pro-
duced, both labeling experiments resulted in a bimodal
distribution (Figure 2). The Significance B could not be
calculated since the underlying assumption in this calcula-
tion is normal distribution of the data. For these samples
the Log2 values were normalized to the most frequent
value and proteins with a fold-change above two in either
of the experiments were selected. This resulted in 200
identified proteins in the low Mankin scored individual
with different levels when comparing the femoral medial
and lateral compartments. The medial femoral compart-
ment showed a higher abundance of 34 proteins out of
which several are known to affect cartilage homeostasis e.
g. TIMP1, TIMP2, SPARC, Col6A1 and Col12A1. Further,
Insulin Growth Factor binding protein 6, 7, 3 and 4 were
also present at a higher level in the medial compartment
of the femoral condyle (Table 3 and Figure 1). Gene ontol-
ogy analysis of biological process showed statistically
Table 2 Significantly regulated proteins in three out of five high Mankin scored individuals
Gene names Protein names UniProt SILAC protein ratio
HM. 1 HM. 2 HM. 3 HM. 4 HM. 5
Significance in 3 of 5 pat.
ENO3 Enolase 3 P13929-2 NR 12.53 NR 10.85 11.41
STAB1 Stabilin 1 Q9NY15 0.18 0.05 0.02 0.42 0.05
TF Serotransferrin A0PJA6 0.16 0.14 0.06 0.12 0.06
SPRR2C Small proline-rich protein Q15515 0.25 0.20 0.09 0.25 NR
DMD Dystrophin P11532-1 0.09 0.08 0.05 0.09 0.08
DPYSL3 Collapsin response mediator protein 4 long variant B3SXQ8 0.14 0.09 0.09 0.11 0.13
Medially abundant protein groups have SILAC ratios >1. Laterally abundant protein groups have SILAC ratios <1. Significant SILAC ratios are in italics.
NR= No Ratio.
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system development, GO:0042127 regulation of cell prolifer-
ation, and GO:0030198 extracellular matrix organization
(Additional file 4: Table S4, sheet 8). In addition, 166 pro-
teins were present at a higher level within the femoral con-
dyle lateral compartment, as compared to the medial
compartment, in the lowMankin scored individual (Table 4,
Additional file 7: Table S7 and Figure 1). The laterally abun-
dant protein groups showed significant term enrichment
results in gene ontology analysis for GO:0030036 actin cyto-
skeleton organization e.g. Destrin, GO:0006006 glucose
metabolic process e.g. Enolase 1 and GO:0006916 anti-
apoptosis e.g. Annexin a1 (Additional file 4: Table S4, sheet
9). Interestingly, the femoral medial and lateral protein
SILAC ratios seen in the LM scored individual were lost in
the HM patients, i.e. the SILAC ratio between the medialFigure 1 Schematic view of the femoral condyles. Proteins listed in gre
condyles of the respective HM and LM knee joint.and lateral femur condyle compartments were close to
one (Tables 3, 4 and Additional file 7: Table S7). Thus, the
quantitative difference in protein secretion between the
medial and lateral compartments found in the low Mankin
scored individual is normalized in the medial and lateral
compartments in the high Mankin scored individuals.
Verification of MS results by ELISA
The MS data of two of the most prominent ECM re-
modeling proteins, i.e. TIMP1 and MMP2, were verified
with ELISA. The ELISA confirmed that the levels of
MMP2 and the known MMP inhibitor TIMP1 were ap-
proximately equal between the medial and lateral com-
partments in the HM individuals. Further the ELISA
also verified that the SILAC ratio values for the LM indi-
vidual showed a medial abundance of TIMP1 (Figure 3).en boxes are the enriched secreted proteins from the medial or lateral
Figure 2 Bimodal distribution of the Log2 values of the protein
H/L ratios from the LM individual. The Log2 values were
normalized to the most frequent value. The bimodal distribution
was inverted from the medially labeled sample (A) to the laterally
labeled sample (B).
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vidual but a SILAC ratio could not be generated. Further
analysis of the MS data showed that the identified MMP2
peptides from the LM individual included the stable iso-
tope labeled amino acids indicating that the MMP2 was
mainly generated from the medial compartment of the
LM femoral condyle. ELISA confirmed this observation
since the lateral chondrocytes from the LM individual did
not secrete any MMP2 at levels detectable by ELISA while
the medial chondrocytes secreted MMP2 in amounts
within the levels from the HM chondrocytes (Figure 3).Taken together ELISA confirmed the MS results for
TIMP1 and MMP2 in all samples.
Proteins uniquely identified in low Mankin scored
chondrocytes
We finally addressed the possibility of identifying unique
proteins only secreted in the LM scored secretome and
not in the secretome of the five HM scored individuals.
Indeed, we found 25 unique proteins in the LM scored
individual where 5 were found in both LM labeled ex-
periments (EPB41L2, AKAP12, FABP3, SCRN-1, CDV3)
(Additional file 8: Table S8).
Discussion
This study was designed to quantitatively compare, using
SILAC technology, the secretome from medial and lateral
femoral condyle chondrocytes obtained from OA patients
undergoing total knee replacement and from an aged and
sex matched individual with no clinical joint disease as a
hypothesis generating approach towards a better under-
standing of OA. The LM sample became highly interesting
since the LM medial side data suggested an early stage
OA compared to the non-affected LM lateral side, such
early stage OA samples are very rare in literature and have
never been examined with the SILAC-technology before.
Results from the first studies that applied the SILAC
technology on articular cartilage were qualitative identify-
ing newly synthesized proteins [22,25]. Later studies
performed by Calamia et al. were both qualitative and
quantitative [23,24] but to our knowledge our study is the
first that qualitatively and quantitatively compares medial
and lateral compartments with different grades of cartilage
degeneration within the same knee.
Previous attempts to label the explant secretome by the
SILAC-technique has proven difficult in articular cartilage
and our own attempt to label the explant secretome gave
similar results (data not shown) as the study by Polacek et
al. where only 25 to 30% of the explant secretome was la-
beled possibly due to the slow cell cycle of chondrocytes
within the cartilage ECM or interference from the ECM it-
self [22]. This is a methodological drawback since quantita-
tive evaluation of SILAC experiments is only interpretable
if the labeled proteome is fully saturated with the stable
isotope. Therefore we widened our study with a first aim
to address the hypothesis whether the monolayer chon-
drocyte culture secretome could mirror the secretome
from native explants and thus partly represent the OA
secretome. The present study demonstrates that a sub-
stantial proportion of the detected proteins secreted from
explants (54%) were also detected among the secreted pro-
teins from monolayer cultures and that several proteins
important for ECM remodeling and reflecting OA disease
were found in the common secretome. Our conclusion is
that although monolayer culture has its limitations in
Table 3 Enriched protein groups in the medial femur condyle of the low Mankin individual and SILAC ratios in
all individuals
Gene names Protein names UniProt SILAC protein ratio SILAC protein ratio
LM I LM II HM. 1 HM. 2 HM. 3 HM. 4 HM. 5
TIMP1* Tissue inhibitor of metalloproteinases 1 P01033 95.7692 0.0027 1.5998 1.1847 1.3414 0.4638 0.8376
IGFBP6* Insulin-like growth factor binding protein 6 P24592 68.0973 0.0018 NR 0.1656 NR 0.1418 1.0172
IGFBP7* Insulin-like growth factor-binding protein 7 Q16270 56.9646 0.0027 1.4450 1.4334 2.8779 1.6507 1.4007
EFEMP1* EGF-containing fibulin-like ECM protein 1 Q12805 55.6707 0.0018 1.1036 0.2390 2.2981 0.3037 0.2289
TIMP2* Tissue inhibitor of metalloproteinases 2 P16035 55.6099 0.0016 1.6216 1.3963 NR 0.9244 1.0870
FSTL1* Follistatin-like protein 1 Q12841 50.4631 0.0036 1.7105 1.1239 3.4944 1.1685 1.0447
CST3* Cystatin-3 P01034 48.8661 0.0038 1.5492 0.5319 NR 0.9870 1.1611
IGFBP3 Insulin-like growth factor-binding protein 3 P17936 47.2340 0.0019 1.2820 0.3277 NR 0.5362 0.8611
CHI3L1* Cartilage glycoprotein 39 P36222 45.1381 0.0040 0.7167 0.8409 3.2179 0.4490 0.3307
LUM* Lumican P51884 44.3039 0.0025 1.4396 1.1753 1.7528 0.9746 0.6962
SERPINE2* Serpin E2 B4DIF2 39.5572 0.0062 0.7233 2.3149 NR 2.2748 NR
IGFBP4* Insulin-like growth factor-binding protein 4 P22692 39.1861 0.0022 0.3036 0.2409 1.4139 0.2510 0.1026
SPARC Osteonectin P09486 36.7189 0.0050 1.1554 0.5516 3.3970 1.1862 0.4348
CTSB* Cathepsin B P07858 36.2281 0.0045 0.8972 1.7551 NR 0.8085 0.7847
PCOLCE* Procollagen C-endopeptidase enhancer 1 Q15113 33.0022 0.0021 1.1413 1.6081 NR 0.6564 0.8188
QSOX1* Quiescin Q6 Sulfhydryl oxidase 1 O00391 30.8917 0.0028 0.3646 0.2358 NR 0.3496 0.1460
SERPINE1* Serpin E1 P05121 24.9099 0.0107 1.9987 0.3301 1.1686 0.8524 0.8781
CYTL1* Cytokine-like protein 1 Q9NRR1 23.5861 0.0038 NR NR NR 0.3065 0.1061
FBN1 Fibrillin-1 P35555 23.5613 0.0042 1.5900 0.7567 1.2034 0.7985 1.1273
COL12A1* Collagen alpha-1(XII) chain Q99715 22.5922 0.0088 0.7853 0.7624 1.2400 0.5582 0.7052
B2M* Beta-2-microglobulin P61769 20.8405 0.0136 1.2302 1.8824 2.5573 1.0522 0.9875
COL6A1* Collagen alpha-1(VI) chain P12109 17.4001 0.0076 1.1075 1.0954 NR 0.9453 1.0361
S100A8* S100 calcium-binding protein A8 P05109 10.4904 0.0016 NR 0.2692 0.4050 0.2882 NR
COL1A2 Collagen alpha-2(I) chain P08123 6.9371 0.0079 0.7605 0.5581 NR 0.3964 0.9798
FN1 Fibronectin 1 Q14328 6.5113 0.0077 NR NR NR 0.6257 NR
COL1A1* Collagen alpha-1(I) chain P02452 5.9307 0.0219 0.9983 1.0441 0.9875 0.9924 1.0064
TPD52L2 Tumor protein D52-like 2 Q5JWU6 3.2973 0.5148 1.2657 NR NR NR NR
CFB Complement factor B Q53F89 3.1730 0.0029 NR NR NR 0.6802 NR
CLEC3B* C-type lectin domain family 3 member B P05452 2.6487 0.0037 NR 2.4076 NR 1.0038 0.7486
TUBB Tubulin beta chain P07437 2.4448 0.5533 1.1187 NR 1.1792 NR NR
CALU Calumenin B3KPG9 2.2541 0.1224 1.1768 1.2613 1.3553 1.6319 1.4068
UGDH UDP-glucose 6-dehydrogenase O60701 2.1286 0.4052 1.1356 NR NR NR NR
DSP* Desmoplakin P15924 2.0360 0.0050 0.2379 0.2814 0.1133 0.1970 NR
IDH1 Isocitrate dehydrogenase 1 (NADP+), soluble O75874 1.9970 0.3614 1.0508 NR NR NR NR
LM I = Low Mankin scored individual experiment one. LM II = Low Mankin scored individual experiment two. HM.1-5 = High Mankin scored individual 1–5.
NR = No Ratio.
* = Proteins identified both in the explant and monolayer secretomes.
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II the identified monolayer secretome indicate an associ-
ation with OA. However, to validate the findings in the
present study there is an absolute need for experimental
improvements in future quantitative studies of the explant
secretome. Such improvements could involve modifica-
tions of the incubation protocols and use of thinnerexplant slices. An alternative labeling method that could
have been used is iTRAQ/TMT but it does not solve the
problem with quantitative analysis of newly synthesized
proteins versus proteins present within the cartilage extra-
cellular matrix.
We studied the secreted proteins from chondrocytes as
they have particular importance in tissue maintenance and
Table 4 The most up-regulated proteins in the LM femur lateral secretome
Gene names Protein names UniProt SILAC protein ratio SILAC protein ratio
LM I LM II HM. 1 HM. 2 HM. 3 HM. 4 HM. 5
UBE2N Ubiquitin-conjugating enzyme E2 N P61088 0.0124 9.5421 0.9613 0.6917 NR NR 0.8378
LXN Latexin Q9BS40 0.0134 5.9971 NR 0.6758 NR NR 0.5899
ACTBL2* Beta-actin-like protein 2 Q562R1 0.0233 4.9112 0.9809 0.5849 0.7814 0.2662 0.5782
TXNDC5 Thioredoxin domain-containing protein 5 Q8NBS9 0.0262 11.4810 0.8763 0.9413 0.8426 0.7740 0.6789
YWHAE 14-3-3 protein epsilon P62258 0.0352 12.7140 1.1072 0.9430 1.0612 0.9204 0.8249
CA2 Carbonic anhydrase 2 P00918 0.0353 11.8720 0.7900 0.8925 1.3874 0.9696 0.5556
FHL1 Four and a half LIM domains protein 1 Q13642-1 0.0356 18.3770 1.0419 0.5525 0.7408 0.9364 1.1789
PFN1 Profilin I P07737 0.0381 10.4650 1.0302 0.8745 0.8038 0.9245 1.0736
PGAM1* Phosphoglycerate mutase 1 P18669 0.0388 10.9160 0.9279 0.7419 0.6064 1.1168 0.9556
TPI Triosephosphate isomerase Q53HE2 0.0424 11.0430 1.0331 1.0640 1.1490 1.0830 1.1780
RSU1 Ras suppressor protein 1 Q15404 0.0428 8.9161 1.0096 0.6922 0.6630 NR 0.8345
GSTO1 Glutathione S-transferase omega-1 P78417 0.0430 23.5890 0.9591 0.8911 NR NR NR
AKR1B1 Aldehyde reductase P15121 0.0439 21.0670 0.7693 1.0281 1.0159 NR 0.8704
STMN1 Stathmin B7Z8N4 0.0452 13.8150 0.9782 0.6731 1.3752 0.6255 0.8742
YWHAB 14-3-3 protein beta/alpha P31946-2 0.0456 48.1920 1.0435 0.9433 0.8530 0.9862 0.8862
ALDOA Fructose-bisphosphate aldolase A P04075 0.0458 11.5280 0.9721 0.6382 0.7641 0.9858 1.0069
YWHAB 14-3-3 protein beta/alpha P31946-1 0.0465 14.3180 NR 0.9594 NR NR NR
MDH1 Malate dehydrogenase, cytoplasmic P40925 0.0465 14.4410 1.0407 0.9923 1.0104 1.0328 0.8833
FTL Ferritin light chain P02792 0.0488 24.5770 0.7289 0.6701 NR NR 0.5221
YWHAZ* 14-3-3 protein zeta/delta P63104 0.0498 18.0160 1.0942 0.9132 1.0023 1.0695 0.9371
EIF5A Eukaryotic translation initiation factor 5A-1 P63241-2 0.0550 16.9460 1.0730 0.8086 NR NR 0.9224
ARHGDIA Rho GDP-dissociation inhibitor 1 P52565 0.0556 14.7570 0.8920 0.6763 NR 0.9223 0.8761
LDHB L-lactate dehydrogenase B chain P07195 0.0582 13.1470 0.9911 0.7294 0.7403 0.8234 0.8016
AKAP12 A-kinase anchor protein 12 Q02952-1 0.1125 22.0240 NR NR NR NR NR
SCRN1 Secernin-1 Q12765 0.1244 11.0260 NR NR NR NR NR
ANXA1* Annexin A1 P04083 0.1407 99.8340 1.8046 0.8261 1.1868 NR 1.2625
EPB41L2 Band 4,1-like protein 2 O43491 0.1462 11.4150 NR NR NR NR NR
FABP3 Fatty acid-binding protein 3 P05413 0.1541 23.3740 NR NR NR NR NR
ANXA5* Annexin A5 P08758 0.1546 6.0555 1.4520 NR 1.1515 NR NR
S100A11* Protein S100-A11 P31949 0.1830 7.7868 1.1976 0.8693 0.8680 0.9675 1.0495
CDV3 Protein CDV3 homolog Q9UKY7-1 0.2226 16.6240 NR NR NR NR NR
Total list is available in the Additional file 7: Table S7.
LM I = Low Mankin scored individual experiment one. LM II = Low Mankin scored individual experiment two. HM.1-5 = High Mankin scored individual 1–5.
NR = No Ratio.
* = Proteins identified both in the explant and monolayer secretomes.
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Further, it is important to study the secreted proteins since
only approximately 7% of the proteins found in the intra-
cellular proteome of chondrocytes may have a direct role
in cartilage ECM synthesis/turnover [23].
The cartilage specimens used in this study were scored
according to the Mankin scoring system [26], a well ac-
cepted and validated score for histological grading of cartil-
age histology [27]. The sample obtained from the patient
with no history of joint disease had a medial Mankin scoreof 2.7 and a lateral Mankin score of 0.3. The different
scores indicated that although the LM scored patient was
asymptomatic from any joint disease the medial compart-
ment was weakly affected and could hypothetically be
regarded as a mild early stage of OA. The changes in pro-
tein secretion between the medial and lateral side are thus
interesting as potential markers of early OA. The single
LM scored sample gave no possibility to draw any statis-
tical conclusions regarding the proteomic state within nor-
mal knee joints. However, the results from the LM scored
Figure 3 ELISA of MMP2 and its inhibitor TIMP1 levels in the HM individuals (A) and the LM individual (B). The two measuring points in
the LML and LMM group represent the two individually labeled culturing experiments of the low Mankin scored individual. High Mankin Scored
Lateral Chondrocytes (HML), High Mankin Scored Medial Chondrocytes (HMM), Low Mankin Scored Lateral Chondrocytes (LML) and Low Mankin
Scored Medial Chondrocytes (LMM).
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independent cultures from the medial and lateral compart-
ments in both labeled and unlabeled medium, respectively.
In this way we could analyze the secretome twice with
inverted labeling conditions, which gave strong technical
data that supported the validity of the results.
In the HM scored OA patients we identified 825 proteins
and 69 of these showed to have a significantly changed
abundance when comparing the femoral medial and lateral
compartments.
The 69 significantly altered proteins were further ana-
lyzed in the DAVID where the proteins were significantly
annotated to the terms inflammatory response and re-
sponse to wounding, which correlates with OA disease
parameters. Enolase 3, Stabilin 1 and Transferrin were
among the six proteins that were significantly regulated in
three of five HM individuals and interestingly annotated
as response to wounding (Table 2). Enolase 3 was medially
elevated and Stabilin 1 and Transferrin were laterally ele-
vated. Interestingly, Stabilin 1 has been shown to be in-
volved in macrophage mediated clearance of SPARC, a
protein which is thought to be involved in mineralization
of bone and is known to be up-regulated in OA [28-31].
In this study Stabilin 1 is less abundant in the HM femoral
medial compartment, which could result in a reduced lo-
calized SPARC clearance contributing to the medial com-
partment OA pathogenesis. Transferrin is known to be
synthesized by hypertrophic chondrocytes and is thoughtto be a chemotactic factor promoting migration of endothe-
lial cells [32]. In OA cartilage this could be a reparative re-
sponse that is down-regulated in the more damaged femur
medial compartment. The remaining three significantly reg-
ulated proteins were not included in a single significantly
enriched GO term; dystrophin (DMD); small proline rich
protein (SPRR2C) and Collapsin response mediator protein
4 long variant (DPYSL3), however SPRR2C was included in
the significantly enriched term GO:0009913 epidermal cell
differentiation. SPRR2C and DPYSL3 have important cellu-
lar functions but no known function in cartilage [33,34].
Interestingly, DMD deficient female mice that had the op-
portunity to voluntary exercise were affected by a signifi-
cantly reduced cartilage thickness and cartilage tissue area
on the proximal femur head compared to wild type control
[35]. The present study shows DMD levels to be signifi-
cantly reduced in the femoral medial more damaged com-
partment compared to the lateral more intact compartment
of the OA knee as evaluated by Mankin score. Thus DMD
may have an ECM preserving role in hyaline cartilage and
interestingly DMD was annotated as GO:0042592 homeo-
static process. To our knowledge this study is the first to
report the involvement of DMD in human OA. Taken to-
gether, the MS results from the HM scored individuals in-
clude a comprehensive secretome of the OA phenotype
together with proteins that may mark the OA progression
between the affected lateral compartment to the heavily af-
fected medial compartment.
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individual to be elevated with a fold change over 2 in the
femoral medial compartment where Cystatin-3, Timp1
and B2M were among the most medially elevated proteins.
Cystatin-3 is a cysteine protease inhibitor, which is known
to modulate the effect of the cysteine proteinase Cathepsin
B [36]. Cathepsin B was also elevated in the femoral med-
ial compartment of the healthy individual, which may indi-
cate an early state of OA in the medial compartment
supported by the facts that elevated Cathepsin B levels has
been found in OA specimens [37]. This is in accordance
with the higher Mankin score in the femur medial com-
partment of the LM scored individual. The effect of
Cathepsin B may however be balanced by the elevated
levels of Cystatin-3.
TIMP1 and TIMP2 are known endogenous inhibitors
of MMPs, which makes them key factors in the cartilage
ECM homeostasis. The elevated TIMP1 and TIMP2
levels found in the LM score individual in the femoral
medial chondrocyte secretome may be a reactive mech-
anism in response to an early OA as the medial condyle
had a higher Mankin score. This was further supported
by the identification of MMP2 in the MS-analysis, even
though the levels in the lateral compartment were not
sufficient for determination of a SILAC-ratio. Further-
more, ELISA confirmed MMP2 to be only present in
the medial secretome of the LM individual. The C-
terminal fragments of Procollagen C-endopeptidase en-
hancer 1 (PCPE) have been shown to inhibit MMP2
[38]. PCPE, also known as PCOLCE, levels were ele-
vated in the LM femoral medial chondrocyte secretome,
which is the same abundance pattern as MMP2 in this
individual. PCOLCE was further expressed in all MMP2
expressing HM scored chondrocytes but was absent in
the secretome from the HM individual nr 3 where no
MMP2 was detected by either MS or ELISA. Taken to-
gether these results indicate that MMP2 and PCOLCE
levels are connected to each other possibly due to a pro-
tective feedback loop. B2M has previously been pro-
posed to be involved in OA pathogenesis as B2M is
expressed in OA cartilage and may influence chondro-
cyte gene expression as well as inhibit proliferation of
chondrocytes [39]. The medially up-regulated B2M
levels found in the LM scored individual could poten-
tially balance the proliferative stress signals that may be
initiated by normal joint usage and/or be the early re-
sponse to a low grade OA and thus a potential early
marker of OA. Our group has previously reported that
chondrocytes from different locations within the knee
joint have different production of proteoglycans and
collagens together with different chondrogenic potential
in vitro [40]. Interestingly, the present study demon-
strates that the differences in abundance of the medi-
ally/laterally regulated proteins in the LM scoredindividual were abolished in OA patients indicating that
a homeostatic balance within the LM scored knee may
be impaired in the HM scored OA knee, however this
hypothesis must be further evaluated in the future.
The low TIMP1 and MMP2 ELISA values for the HM3
patient (with the lowest Mankin score within the HM
group) could indicate an intermediate disease stage for
this patient, which is further supported by the similarities
in SILAC ratios with the LM scored patient. Such SILAC
ratios were seen for IGFBP7, EFEMP1, FSTL1, CHI3L1,
IGFBP4, SPARC and B2M. EFEMP1 or formerly Fibulin-3
was demonstrated to have a negative regulation on chon-
drocyte differentiation and was proposed as a diagnostic
biomarker for OA [41,42]. FSTL1 has been demonstrated
to be correlated to the severity of OA disease as well as
CHI3L1 [43-45]. SPARC and B2M are correlated to OA
while the IGFBP7 has not been correlated to OA previ-
ously [30,39,46]. IGFBP4 is suggested to inhibit the canon-
ical Wnt signaling pathway, which makes elevated levels
of IGFBP4 on the medial side in the LM scored specimen
an interesting finding as stimulated Wnt signaling is
known to be involved in OA pathogenesis [47-50]. This
SILAC ratio pattern may indicate an OA initiation in the
medial femur condyle of the LM scored individual and a
counteracting reparative process, which has balanced car-
tilage homeostasis in this aged and sex matched individual
who never developed clinical signs of OA. When the lat-
eral side becomes more affected by the OA, as in the
HM3 patient, the ratio becomes smaller towards a ratio
close to one seen in the highest Mankin scored patients.
One of the medially abundant proteins in the LM in-
dividual is the Cytokine like protein 1 (CYTL1) which is
only found in two HM patients with an elevated level on
the femur lateral side. CYTL1 is a novel autocrine regu-
latory factor that regulates chondrogenesis of mouse
mesenchymal cells [51]. In a recent knockout study dele-
tion of the CYTL1 gene did not affect chondrogenesis or
cartilage development. However, CYTL1 knockout mice
were more sensitive to osteoarthritic cartilage destruction
and expression levels of CYTL1 were markedly decreased
in OA cartilage of humans and experimental mice [52].
Our SILAC data thus support the hypothesis that CYTL1
is required for the maintenance of cartilage homeostasis,
and loss of CYTL1 function is associated with OA cartil-
age destruction.
SILAC ratios showing laterally abundant proteins in
the LM individual were also analyzed and showed sev-
eral proteins designated as anti-apoptotic (e.g. Annexin
1 and 5). Chondrocyte derived S100A8 and S100A9 have
a potential role in inflammatory arthritis in initiating
early cartilage degradation by up-regulating MMPs and
aggrecanases [53], partly supported by our results with
laterally abundant S100A11 and medially abundant
S100A8 in the LM scored individual.
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the LM scored secretome that were not found in any of the
high Mankin scored patients. Interestingly we found 25
unique proteins in the LM scored secretome and all pro-
teins found were elevated on the lateral femoral side except
for the coatomer subunit zeta-1. Five of the proteins were
also found in the inversely labeled LM scored experiment i.
e. EPB41L2, AKAP12, FABP3, SCRN-1, CDV3 and are thus
of high relevance and certainty. The A-kinase anchor pro-
tein 12 (AKAP12) has a pivotal role in regulation of cellular
adhesion dynamics and is also a putative inhibitor of angio-
genesis through down-regulation of MMP9 expression [54].
MMP9 inhibition through AKAP12 may thus suppress the
typical hallmarks of OA in the LM scored individual i.e.
ECM degradation and angiogenesis in the cartilage.
Secernin-1 (SCRN-1) regulates exocytosis in mast cells and
has recently been proposed as a prognostic marker in syn-
ovial sarcoma where high expression is associated with a
better prognosis possibly due to a higher grade of differenti-
ation [55,56]. Thus, high SCRN-1 levels could mark a dif-
ferentiated cartilage, and in the case of the LM individual
mark a more dedifferentiated OA-like state in the medial
compartment as the levels were medially lowered. However,
these conclusions may be tissue specific as SCRN-1 ex-
pression has also been proposed as a prognostic marker
in colorectal cancer where elevated expression was as-
sociated with a worse prognosis [57]. The FABP3 pro-
tein is related to regulation of apoptosis where it both
promotes and inhibits apoptosis, which may be of inter-
est in further studies regarding its role in OA [58-60].
Among proteins that only generated a protein SILAC
ratio in one LM experiment PPP2CA is the catalytic
subunit of protein phosphatase 2A (PPP2A). Inhibition
of PPP2A in TGFbeta stimulated normal human chon-
drocytes has an anti apoptotic effect [61]. Inhibition of
PPP2A is also suggested to have a chondrogenic effect
through the protein kinase A signaling pathway in experi-
ments with chicken chondrocytes in vitro [62,63]. Our re-
sults indicate that PPP2CA levels are lowered in the medial
secretome of the LM individual and not present in the HM
secretomes. This could indicate that loss of PPP2CA is an
early OA marker in the medial compartment of the LM in-
dividual that is completely lost in the end stage of the dis-
ease. However, the actual role of PPP2CA in OA needs to
be further investigated.
Conclusions
We have demonstrated that proteins detected in the
monolayer cultured chondrocyte secretome partly mir-
rors the proteins detected in the explant secretome and
allows for quantitative studies. By applying the SILAC
technology we demonstrated that the relative abundance
of proteins significantly differed between chondrocytes
isolated from the lateral and medial femoral condyle ofOA patients (represented by Enolase 3, Stabilin 1, Transfer-
rin, DMD SPRR2C and DPYSL3). Furthermore, in the LM
scored chondrocyte secretome there were several proteins
with a high SILAC ratio between the femur medial and lat-
eral compartment e.g. MMP2 and TIMP1, that in combin-
ation with the Mankin scores may suggest that the LM
medial femoral condyle secretome represents an early OA.
Such unique data has to our knowledge never been pub-
lished. Thus the differently expressed proteins could be po-
tential markers of early OA degradation e.g. PPP2CA,
IGFBP7, EFEMP1, FSTL1, CHI3L1, IGFBP4, SPARC and
B2M. The high SILAC ratios in LM scored chondrocyte
secretomes are lost in the HM scored chondrocyte
secretomes, which indicates a shift in protein expression as
the HM lateral femur compartment becomes more affected
by the upgraded OA. Also, our data confirm experimental
findings in mice regarding the role of DMD and CYTL1 in
OA. There are also additional unique proteins for the LM
scored patient that could represent healthy cartilage or
early OA and could have potential for future functional
studies e.g. new drug targets. For highlighted findings see
list of proteins highlighted in the discussion.
List of proteins highlighted in the discussion
Gene name
























Patient data and cartilage harvest
Human cartilage material used in this study was ac-
quired from seven female total knee replacement cases
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macroscopically healthy knee cartilage. From two individ-
uals, 73 and 82 years old undertaking total knee replace-
ment, cartilage explants were obtained from the medial
and lateral femur condyles. Chondrocytes for monolayer
cultures were separately extracted from the medial and lat-
eral femur condyle of the remaining five total knee re-
placement patients, 63, 67, 69 and two 72 years of age.
The sixth monolayer culture was performed from macro-
scopically healthy cartilage biopsies taken from a patient
70 years of age undertaking leg amputation due to sar-
coma with a macroscopically healthy knee cartilage. All
samples were provided by the orthopedic surgeon depart-
ment at Sahlgrenska University Hospital in Gothenburg
with patient informed consent. Cartilage donations were
approved by the ethical committee at the Sahlgrenska
Academy at the University of Gothenburg, Gothenburg,
Sweden.
Biopsy preparation for Mankin classification
Biopsies were isolated and a section of each biopsy was
fixated in Histofix (Histolab products, Gothenburg,
Sweden) for 24 hours, dehydrated with serial baths of
increasing ethanol concentrations and embedded in
paraffin. The paraffin embedded biopsies were cut into
5 μm sections onto microscope glass slides (Superfrost
Plus, Menzel-Gläser, Germany), deparaffinized, Saffranin
O stained and examined in a light microscope (Nikon,
Japan). The biopsies were subsequently classified accord-
ing to the modified Mankin score where the inspection
of the tidemark has been excluded [26]. Mankin score is
presented as mean out of three individual blinded scoring
sessions performed by three experienced technicians.
The OA specimens achieved higher Mankin scores and
are in the following text accordingly denoted high
Mankin (HM) patients while the unaffected cartilage
specimen is denoted Low Mankin scored (LM).
Cartilage explant culture
Cartilage explants from two individuals were used for in-
vestigation of the explant secretome. Individual speci-
mens were collected from the medial and lateral femur
condyles respectively. Samples were cut into small pieces
(approximately 2 mm3) and cultured for SILAC analysis.
Femoral medial explants were incubated in SILAC
DMEM/F12 medium containing 0.1 mg/mL of stable
isotope labeled (heavy) arginine and lysine (U-13C6-Ar-
ginine and U-13C6-Lysine, Invitrogen) while femoral lat-
eral explants were incubated in SILAC DMEM/F12
supplemented with 0.1 mg/mL normal (light) arginine
and lysine (Invitrogen). The explant medium was
changed daily for 10 days. Equal volumes (2 mL) of the
conditioned explant culture medium from stable isotope
labeled and unlabeled cultures were mixed prior toproteomic analysis. Duplicate samples of medium collected
at day 2 and 10 from each patient were analyzed resulting
in eight data-files representing the explant secretome.
Stable isotope labeling of chondrocytes in
monolayer culture
Chondrocytes were separately extracted, as described earl-
ier [6], from the medial and lateral femur condyle of five
HM-scored patients affected with severe OA and from
one LM-scored individual with macroscopically healthy
knee cartilage. The extracted chondrocytes were seeded, at
16 × 103 cells/cm2, in SILAC DMEM/F12 medium (HM
1–5 and LM Experiment I). For the six chondrocyte cul-
tures from the medial femur condyle the SILAC DMEM/
F12 medium contained 0.1 mg/mL of stable isotope la-
beled arginine and lysine (U-13C6-Arginine and U-
13C6-
Lysine, Invitrogen) and for the six chondrocyte cultures
from the lateral femur condyle the SILAC DMEM/F12
medium contained 0.1 mg/mL of normal arginine and ly-
sine (Invitrogen). In addition, the LM scored cells were
also cultured with the inverted labels (LM experiment II).
Medium was changed every third day. All cultures were
conducted in 37°C, 95% humidity and 5% CO2.
Protein enrichment and digestion
Supernatants from the cartilage explant cultures were col-
lected after 2 and 10 days, respectively. Two aliquots of
2 mL from each time point were concentrated to 50 μL
and the proteins were separated on SDS-PAGE gels as de-
scribed below. After monolayer expansion of chondrocytes




for 5–6 cell doublings cells were conditioned in serum-
free medium for 24 hours and subsequently the serum free
conditioned media were collected and processed prior to
MS-analysis. Equal volumes (2 mL) of the conditioned cell
culture medium from SILAC-labeled and unlabeled cul-
tures were mixed and the volume was reduced from 4 mL
to approximately 50 μL on the Amicon Ultra-2 centrifugal
concentrators (Millpore) with a molecular cut-off of
3,000 Da. The concentrated protein secretome in the
retentate was separated by denaturing one-dimensional
polyacrylamide gel electrophoresis (1-D SDS-PAGE). The
concentrated protein solution (25 μL) was supplemented
with NuPage LDS-sample buffer (Invitrogen) and
dithriothreitol to a final concentration of 50 mM. Proteins
were reduced and denatured by heating at 70°C for 10 mi-
nutes and loaded onto 4-12% Bis-Tris (NuPAGE® Novex)
precast polyacrylamide gels, post-separation, proteins
were visualized by Coomassie colloidal blue staining
(Invitrogen). For in-gel trypsin digestion each gel lane was
divided into 15 equally sized gel slices and subjected to au-
tomated trypsin digestion on the BioMek 2000 worksta-
tion equipped with a vacuum manifold. 96-well plates
Stenberg et al. Proteome Science 2013, 11:43 Page 12 of 15
http://www.proteomesci.com/content/11/1/43supplemented with a 7 μL volume of C18 reversed phase
chromatographic resin (Lab-in-a-Plate Flow-Thru Plate,
Glygen) were used for vacuum filtration and sample clean-
up. The work-flow essentially followed the protocol previ-
ously described [64] except that the peptide extraction was
performed twice with 0.2% trifluoroacetic acid (TFA) to
allow for peptide binding to the C18 resin of the filter
plates. Finally, peptides were eluted in two times 40 μL of
60% acetonitrile in 0.1% TFA and the eluted fractions were
evaporated to dryness in a speedvac centrifuge. Prior to
LC-MS/MS analysis samples were re-dissolved in 0.1% for-
mic acid. For an experimental line-up see Figure 4.
LC-MS/MS analysis
Tryptic peptides, from digestion of the gel separated
secretome, were separated on a 15 cm capillary column
(Zorbax SB300 C18, 0.075 mm ID) by reversed phase
chromatography. Peptides were reconstituted in 0.1% for-
mic acid, loaded onto the column in eluent A (0.1% formic
acid) and separated with a linear gradient from 3% to 60%
eluent B (84% acetonitrile in 0.1% formic acid) at a flow
rate of 250–300 nL/min. Gradient lengths were 130 min
and the LC system (Ettan MDLC, GE Healthcare Life
Sciences, NJ, USA) was directly coupled in-line with a
LTQ-FTICR instrument (Thermo Fisher Scientific) via a
nano-electrospray source (Thermo Fisher Scientific). The
source was operated at 1.4 kV, with no sheath gas flow and
with the ion transfer tube at 200°C. The mass spectrometer
was programmed for acquisition in a data dependent
mode. The survey scans were acquired in the FTICR massFigure 4 Representative biopsy images and experimental line-up. Saf
condyle (B), representative HM lateral femur condyle (D) and representativ
procedure where chondrocytes were extracted from lateral and medial fem
medium conditioning and analyzed with MS (C).analyzer at a resolution of 50,000 at m/z 400 and covered
the m/z range 300–2,000, the 7 most intense peaks in each
full mass scan, with charge state ≥ 2 and intensity above a
threshold of 100, were selected for fragmentation in the
linear ion trap (LTQ) by collision induced dissociation
(CID). CID fragmentation was performed with normalized
collision energy of 35%, activation q = 0.25, activation time
of 30 ms and three microscans were averaged. For all frag-
mentation events dynamic exclusion was enabled with a
repeat count of 2, peaks selected for fragmentation more
than twice within 30 s were excluded from selection (20 p.
p.m. window) for 180 seconds, the maximum number of
excluded peaks was 200.
Protein identification and quantification
Raw data containing full-scan spectra acquired in profile
mode and centroid MS/MS spectra, from the analysis of
tryptic peptides, were processed using the MaxQuant soft-
ware version 1.2.0.18 [65]. Default settings were used for
feature extraction and first search for recalibration was
performed against the human first search database pro-
vided with the software. The Andromeda search engine
[66] integrated into the MaxQuant package was used for
peptide identification and searches were performed against
the IPI human database (version 3.68, 8,7061 sequences).
Parameters for identification and quantification were set
as follows: variable modification; oxidation of methionine
and acetylation of the N-terminal, fixed modification;
carbamidomethylation of cysteine, MS/MS tolerance
0.5 Da, peptide and protein FDR was set to 0.01 and forfranin O staining of the LM lateral femur condyle (A), LM medial femur
e HM medial femoral condyle (E). Schematic view of the experimental
oral condyle of the same knee joint, labeled in culture, incubated for
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lys6. SILAC protein ratios are determined as the median of
all peptide ratios assigned to the protein. For quantification
a minimum peptide ratio count of two was set for each pro-
tein. To ensure that the Log2 values of the normalized pro-
tein H/L ratios followed a normal distribution and were
centered around zero, histograms were plotted. Calculation
of Significance B was done on the Log2 values of protein
H/L ratios and intensities using the Perseus module (ver-
sion 1.2.0.17) available in the MaxQuant environment.
Threshold value for the significance B was set to 0.05 and
the truncation was based on the Benjamini-Hochberg FDR.
Comparison of datasets
MaxQuant result files (ProteinGroups.txt and peptides.txt),
including information on identified proteins and peptides
were imported into the ProteinCenter software version
3.8.2014 (Proxeon Bioinformatics, Odense, Denmark). Data
were filtered so that each identified protein contained at
least 2 unique peptides and identified proteins were clus-
tered, based on peptide sharing, into groups of indistin-
guishable proteins. All protein identifications originating
from the analysis of culture media from explant incubations
(eight samples) were merged into one single data set and all
protein identifications from monolayer cultures (five sam-
ples) were merged into a second data set. Comparison of
the two datasets was performed in the Protein Center soft-
ware. An additional comparison was made to 100 proteins
identified from monolayer-cultured chondrocytes in a study
by Polacek et al. [22]. These protein identifiers were manu-
ally added to the ProteinCenter software.
Gene ontology analysis
The proteins that were differentially abundant when com-
paring the medial and lateral HM femoral condyle and the
differentially abundant proteins when comparing the med-
ial and lateral LM femoral condyle were put in a biological
context by gene ontology (GO) analysis using Database
for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7 [67,68]. The protein lists were uploaded
to DAVID with official gene symbol as identifier and
the gene ontology term Biological Process FAT (GOT
ERM_BP_FAT) was chosen for gene ontology analysis.
Functional annotation chart was used for analyzing the
functional annotation results. Genetic association database
for disease was used in DAVID to analyze if the proteins
common for both monolayer chondrocytes and explants
were associated with any known disease.
Verification of MS quantifications by Enzyme Linked
Immunosorbent Assay (ELISA)
TIMP metallopeptidase inhibitor 1 (TIMP1) and matrix
metalloproteinase-2 (MMP2) protein levels in the
chondrocyte-conditioned media used for SILAC analysiswere determined with ELISA according to the manufac-
tures recommendations (R&D Systems, MN, USA). The
samples were diluted 1:49 for the TIMP1 ELISA and used
undiluted for the MMP2 ELISA. Optical density of each
well was determined with an Infinite® F50 Absorbance
microplate reader set to measure 450 nm with the wave-
length correction set to 540 nm (TECAN, Männedorf,
Switzerland). Measurement data and protein amounts were
calculated using the Magellan™ V6.6 software (TECAN).
Additional files
Additional file 1: Table S1. Proteins identified in cellmedium from explant
cultures of two OA patient samples (Patient 1 and Patient 2). Cellmedia
collected at day 2 and 10 were collected and analysed in duplicates.
Additional file 2: Table S2. Proteins identified in cellmedium from
monolayer cultures of five OA patient samples.
Additional file 3: Table S3. Proteins common for the combined OA
explant seretome and the combined high Mankin scored monolayer
secretomes.
Additional file 4: Table S4. Gene Ontology analysis.
Additional file 5: Table S5. Proteins identified in cellmedium from
monolayer cultured chondrocytes of one LM-scored patient sample.
Duplicate samples were individually SILAC labelled and processed in
parallel. LM Exp I = Low Mankin label experiment one, LM Exp II = Low
Mankin label experiment two.
Additional file 6: Table S6. All medially/latterally regulated proteins in
the HM secretomes. Silac protein ratio>1= Femur medial abundance.
Silac protein ratio<1= Femur lateral abundance. HM=High Mankin scored
individual. NR= No Ratio.
Additional file 7: Table S7. Up-regulated proteins in the LM femur
lateral secretome. LM I=Low Mankin scored individual experiment one.
LM II=Low Mankin scored individual experiment two. HM.1-5=High
Mankin scored individual 1-5. NR=No Ratio.
Additional file 8: Table S8. Proteins uniquely found in the LM
secretome.
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